Loading stock data…
$4.76-0.02 (-0.31%)
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States.
Savara Inc. in the Healthcare sector is trading at $4.76 with a market capitalization of $1.1B. Wall Street consensus targets $11.06 (9 analysts), implying a +132.0% move over the next 12 months. The stock is currently 32% below its 52-week high of $7.00, remaining 12.7% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$40.97M↓ | -$38.14M↓ | -$33.42M↓ | -$30.25M↑ | -$31.44M |
| Net Income | -$40.23M↓ | -$37.28M↓ | -$32.24M↓ | -$29.56M↑ | -$30.40M |
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3...